Tag Archives: R&D
Tough Times Ahead for New Medicines under NHS England?
By Leela Barham
You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages. They’re important, [...]
Posted in Europe, Global, Guest Blog, healthcare, pricing Also tagged National Health Service, NHS, NICE, value, value-based pricing Leave a comment
Emerging Countries' R&D: A Contest, but No Wipe Out
Emerging country markets are widely viewed as Big Pharma’s ace in the hole to replace declining rates of innovation in the US and Europe, with numerous studies claiming the BRICK nations (the ‘K’ is from South Korea) are at the center of a revolutionary global shift in the source points for new ideas — what [...]
Posted in Emerging Markets, Global, IP, R&D Also tagged BRIC, BRICK countries, Emerging Markets 2 Comments
Pharma's Shifting Needs for Scientific Talent
By Susan Haigney.
Developing and maintaining the right labor pool is an ongoing challenge for any industry, and it is one that the pharmaceutical industry also is facing. Recent attention in the pharmaceutical industry has focused on the restructuring that has occurred and that is still occurring among the large pharmaceutical companies. [...]

Global Biosimilars Market to Reach $2.4 Billion in 2013